Sign Up
OverviewAPI
The popularity of GLP-1 agonists, such as Wegovy and Ozempic, is a hot topic during Q3 earnings calls. Retail investors are flocking to Eli Lilly after its weight-loss drug Zepbound's approval. The surge in popularity of weight-loss drugs may have a positive impact on the fitness industry and discretionary spending sectors. However, there are concerns about the potential long-term financial impact of GLP-1 drugs on medical device stocks.

Ask a question